Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17548830 | 0.98 | PTGS2 (0.40) | PTGS2PTGS1ACHETDP1RPS6KA3 | |
| SCHEMBL4549715 | 0.98 | PTGS2 (0.40) | PTGS2PTGS1ACHETDP1RPS6KA3 | |
| SCHEMBL803431 | 0.98 | PTGS2 (0.40) | PTGS2PTGS1ACHETDP1RPS6KA3 | |
| SCHEMBL14211939 | 0.96 | PTGS2 (0.39) | PTGS2PTGS1ACHETDP1RPS6KA3 | |
| SCHEMBL803253 | 0.93 | PTGS2 (0.38) | PTGS2PTGS1 | |
| SCHEMBL172423 | 0.91 | ACHE (0.48) | PTGS2PTGS1ACHETDP1RPS6KA3 | |
| SCHEMBL18503372 | 0.89 | CYP1A2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL13417792 | 0.89 | AKR1C3 (0.43) | PTGS2PTGS1RPS6KA3PDE3BPDE3A | |
| SCHEMBL17192339 | 0.89 | AKR1C3 (0.43) | PTGS2PTGS1RPS6KA3PDE3BPDE3A | |
| SCHEMBL17570168 | 0.88 | ACHE (0.46) | PTGS2PTGS1ACHETDP1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 574 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239818-A | Preparation method of fluorobiphenyl compound | 沈阳中化农药化工研发有限公司 | 2024-06-25 | — | — | CN | claimed |
| US-12043781-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2024-07-23 | — | — | US | disclosed |
| US-20240228879-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE THEREOF | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| WO-2024133363-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| CN-118239818-A | Preparation method of fluorobiphenyl compound | 沈阳中化农药化工研发有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240067879-A1 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| CN-117603174-A | Method for preparing benzoepoxidation heterocycle by visible light photocatalysis | 河南大学 | 2024-02-27 | — | — | CN | disclosed |
| WO-2024017812-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2024-01-25 | — | — | WO | disclosed |
| US-20240026223-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-4306615-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2024-01-17 | — | — | EP | disclosed |
| US-20090141215-A1 | POLYMERIZABLE COMPOUNDS | MERCK PATENT GESELLSCHAFT (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090103011-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GESELLSCHAFT (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20080308768-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-7462297-B2 | Chiral dopants having a laterally alkylated phenyl structural element | MERCK PATENT GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-20080191166-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT (DE) | 2008-08-14 | — | — | US | disclosed |
| US-7371437-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| US-20080090026-A1 | Liquid-crystal display | MERCK PATENT GMBH | 2008-04-17 | — | — | US | disclosed |
| US-7195719-B1 | High polarization ferroelectric liquid crystal compositions | DISPLAYTECH, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7195719-B1 | High polarization ferroelectric liquid crystal compositions | DISPLAYTECH, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070051920-A1 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090026-A1 | Liquid-crystal display | KLK3, LPXN, BPHL | PTGS2 4553/4885PTGS1 4286/4885ACHE 4670/4885 |
| US-20090141215-A1 | POLYMERIZABLE COMPOUNDS | VCL, LCP1, LPXN | PTGS2 3982/4885PTGS1 3855/4885ACHE 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.